FibroBiologics (NASDAQ:FBLG - Get Free Report)'s stock had its "buy" rating reiterated by stock analysts at D. Boral Capital in a research report issued on Friday,Benzinga reports. They presently have a $16.00 price objective on the stock.
A number of other analysts have also recently weighed in on FBLG. EF Hutton Acquisition Co. I upgraded shares of FibroBiologics to a "strong-buy" rating in a report on Wednesday, September 4th. Maxim Group assumed coverage on FibroBiologics in a research note on Tuesday, September 24th. They set a "buy" rating and a $12.00 price objective for the company. HC Wainwright restated a "buy" rating and issued a $12.00 target price on shares of FibroBiologics in a report on Wednesday, November 13th. Finally, Rodman & Renshaw assumed coverage on FibroBiologics in a report on Thursday, December 12th. They set a "buy" rating and a $12.00 target price for the company. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $13.00.
Check Out Our Latest Report on FibroBiologics
FibroBiologics Stock Performance
FBLG traded up $0.05 during trading on Friday, reaching $2.36. The stock had a trading volume of 135,912 shares, compared to its average volume of 243,943. The stock has a 50 day moving average of $2.68 and a two-hundred day moving average of $3.34. FibroBiologics has a 1-year low of $1.08 and a 1-year high of $55.00.
Institutional Trading of FibroBiologics
Hedge funds have recently modified their holdings of the business. The Manufacturers Life Insurance Company purchased a new stake in shares of FibroBiologics in the third quarter worth approximately $32,000. Jane Street Group LLC purchased a new stake in FibroBiologics in the 3rd quarter worth approximately $37,000. Mercer Global Advisors Inc. ADV acquired a new stake in shares of FibroBiologics during the 2nd quarter valued at $51,000. Cahaba Wealth Management Inc. purchased a new position in shares of FibroBiologics during the 2nd quarter valued at $73,000. Finally, Symphony Financial Ltd. Co. purchased a new position in shares of FibroBiologics during the 3rd quarter valued at $76,000.
FibroBiologics Company Profile
(
Get Free Report)
FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.
Featured Stories
Before you consider FibroBiologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and FibroBiologics wasn't on the list.
While FibroBiologics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
